Skorpios Trust Sells 2,000,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Skorpios Trust lessened its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 22.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,906,181 shares of the company's stock after selling 2,000,000 shares during the period. Stoke Therapeutics makes up approximately 99.8% of Skorpios Trust's holdings, making the stock its largest position. Skorpios Trust owned about 13.04% of Stoke Therapeutics worth $76,175,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Mesirow Financial Investment Management Inc. purchased a new stake in shares of Stoke Therapeutics during the third quarter worth about $192,000. Los Angeles Capital Management LLC lifted its holdings in shares of Stoke Therapeutics by 54.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company's stock worth $1,266,000 after acquiring an additional 36,240 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Stoke Therapeutics in the 3rd quarter worth about $160,000. Charles Schwab Investment Management Inc. boosted its position in shares of Stoke Therapeutics by 9.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company's stock valued at $3,885,000 after buying an additional 26,870 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Stoke Therapeutics by 1,589.7% in the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company's stock worth $936,000 after purchasing an additional 71,647 shares during the last quarter.

Remove Ads

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $78,852.60. Following the transaction, the chief executive officer now directly owns 68,671 shares of the company's stock, valued at $877,615.38. The trade was a 8.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 13,945 shares of the company's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the completion of the transaction, the insider now owns 47,332 shares of the company's stock, valued at approximately $604,902.96. This represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 52,849 shares of company stock valued at $688,721 over the last quarter. Corporate insiders own 11.30% of the company's stock.

Stoke Therapeutics Stock Performance

STOK traded up $0.58 during trading on Wednesday, reaching $8.16. The company's stock had a trading volume of 559,060 shares, compared to its average volume of 839,278. Stoke Therapeutics, Inc. has a 52-week low of $5.60 and a 52-week high of $17.58. The company's fifty day moving average price is $10.04 and its 200-day moving average price is $11.95. The company has a market capitalization of $432.21 million, a price-to-earnings ratio of -3.89 and a beta of 0.99.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, February 18th. HC Wainwright lifted their price objective on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, February 19th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.